Literature DB >> 2702642

Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.

J W Wallen1, R L Cate, D M Kiefer, M W Riemen, D Martinez, R M Hoffman, P K Donahoe, D D Von Hoff, B Pepinsky, A Oliff.   

Abstract

Múllerian Inhibiting Substance (MIS) is a testicular hormone that promotes involution of the Múllerian duct during embryogenesis. The Múllerian duct gives rise to adult female reproductive ducts including the fallopian tubes, uterus, and upper vagina. Thus, testicular MIS ensures the regression of female sex organ primordia. Partially purified bovine MIS was reported to inhibit proliferation of tumor cells derived from human gynecological cancers. These observations suggest that MIS might be an effective anticancer agent for some human tumors. Recombinant human MIS (rHu-MIS) has recently become available. To assess the antiproliferative activity of rHu-MIS, we examined its effects on 11 ovarian, six endometrial, and two nongynecological human tumor cell lines. rHu-MIS had no effect on proliferation of these cell lines in five independent assays. Forty-three primary human tumor explants were also examined in human tumor colony forming assays, gel-supported primary culture assays, and subrenal capsule assays. rHu-MIS significantly inhibited the growth of five of these tumors including four ovarian and one small cell lung cancer explant. The four ovarian cancer responses include three of 13 (23%) explants tested in human tumor colony-forming assays and one of eight (12.5%) explants tested in gel-supported primary culture assays. We conclude that rHu-MIS may have antiproliferative activity against some human ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702642

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  Embryology and classification of intersex states.

Authors:  N Josso
Journal:  Indian J Pediatr       Date:  1992 Jul-Aug       Impact factor: 1.967

2.  Immunocytochemical demonstration of the binding and internalization of growth hormone in GERL of Chang hepatoma cells.

Authors:  J J Wang; J P Chang; C S Teng
Journal:  Cell Tissue Res       Date:  1990-11       Impact factor: 5.249

3.  Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.

Authors:  Erica Gentilin; Mariella Minoia; Marta Bondanelli; Federico Tagliati; Ettore C Degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2016-09-01       Impact factor: 3.633

Review 4.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

5.  A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours.

Authors:  A P Wilson; H Fox; I V Scott; H Lee; M Dent; P R Golding
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

6.  Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.

Authors:  N Yamada; M Kato; P ten Dijke; H Yamashita; T K Sampath; C H Heldin; K Miyazono; K Funa
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

7.  The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics.

Authors:  Maximilian Boesch; Alain G Zeimet; Daniel Reimer; Stefan Schmidt; Guenther Gastl; Walther Parson; Franziska Spoeck; Jiri Hatina; Dominik Wolf; Sieghart Sopper
Journal:  Oncotarget       Date:  2014-08-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.